T-cell receptor recognizing tetanus toxoid-derived peptide–MHC complex (TT-specific TCR)

T-cell receptors (TCRs) recognizing tetanus toxoid-derived peptide–MHC complexes are specialized heterodimeric surface receptors that mediate the adaptive immune response to Clostridium tetani [PubMed: 2461024]. These receptors specifically recognize processed peptides from the tetanus toxoid (TT) protein, such as the widely studied p2 (830–843) or p30 epitopes, when presented by Major Histocompatibility Complex (MHC) molecules [Journal of Immunology, 1989]. This interaction is fundamental to the efficacy of tetanus vaccines, as it triggers the activation and expansion of memory T cells that provide long-term protection [NIH: Tetanus Vaccination]. In therapeutic contexts, TT-specific TCRs are utilized as universal helper epitopes in cancer vaccines and as scaffolds for TCR-engineered T-cell therapies (TCR-T) to enhance anti-tumor immunity [Cancer Immunology Research, 2018]. They also serve as critical diagnostic tools for monitoring T-cell responses in clinical trials using peptide-MHC multimers [Nature Reviews Immunology, 2002]. The high frequency of TT-specific T cells in the general population makes these TCRs an ideal model for studying human T-cell biology and developing novel immunotherapeutic strategies [Frontiers in Immunology, 2020].

Other names

Tetanus toxoid-specific T-cell receptorTT-pMHC-specific TCRAnti-tetanus toxoid TCRT-cell receptor recognizing TT-derived peptide–MHC complex

The TCR specifically binds to tetanus toxoid peptides presented by MHC molecules, initiating a signal transduction cascade via the CD3 complex that leads to T-cell activation and cytokine production [PubMed: 7507076].